Biogen in promising but risky limelight after Eli Lilly’s Alzheimer’s drug fails | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 25 November, 2016 by The TZ Newswire Staff

Biogen in promising but risky limelight after Eli Lilly’s Alzheimer’s drug fails

Biogen is using the same scientific approach to treating the disease as Eli Lilly.
read more

See also
- Next Article Where Bitcoin Mining Pools Stand on Segregated Witness
- Previous Article GlaxoSmithKline Studies EPO-Like Anemia Drug (GSK)
Editorial Calender

November 2016

M T W T F S S

1 2 3 4 5 6

7 8 9 10 11 12 13

14 15 16 17 18 19 20

21 22 23 24 25 26 27

28 29 30

« Oct Dec »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar